Dr. Chengliang Yang’s research at the PROOF Centre of Excellence focuses on non-invasive biomarkers that can diagnose and/or predict organ failure and other clinically-important indications. His research interests focus on long COVID pathogenesis and biomarker discovery, alpha-1 antitrypsin deficiency and cardiothoracic transplantation.

Moreover, he has acquired several research funding as (Co-) Principal Investigator or Co-Investigator and published > 25 first- and last-author publications in medical peer-reviewed journals such as Lancet, Lancet Resp Med, JAMA Intern Med, PNAS and serves as Review Editor at the Thoracic Surgery section of Frontiers in Surgery.

He is specifically interested in the metabolomic biomarkers discovery of acute heart allograft rejection and chronic lung allograft dysfunction.